These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 37292376)
1. A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Moreno L; Teira P; Croop JM; Gerber NU; André N; Aerts I; Gros Subias L; De Wilde B; Bautista F; Turpin B; Kunduri S; Hamidi A; Lawrence T; Streby KA Front Pediatr; 2023; 11():1183295. PubMed ID: 37292376 [TBL] [Abstract][Full Text] [Related]
2. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636 [TBL] [Abstract][Full Text] [Related]
4. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575 [TBL] [Abstract][Full Text] [Related]
5. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Chesney JA; Puzanov I; Collichio FA; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan T; Hauschild A; Lebbé C; Joshi H; Snyder W; Mehnert JM J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142291 [TBL] [Abstract][Full Text] [Related]
6. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410 [TBL] [Abstract][Full Text] [Related]
12. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296 [TBL] [Abstract][Full Text] [Related]
13. Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. Kleemann J; Jäger M; Valesky E; Kippenberger S; Kaufmann R; Meissner M Cancer Manag Res; 2021; 13():5699-5709. PubMed ID: 34290528 [TBL] [Abstract][Full Text] [Related]
14. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors. Barker CA; D'Angelo SP; Wasilewski G; Steckler AM; Lian M; Zhang Z; Chapman PB; Shoushtari AN; Ariyan CE Radiother Oncol; 2024 Nov; 200():110478. PubMed ID: 39159678 [TBL] [Abstract][Full Text] [Related]
16. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. Hecht JR; Raman SS; Chan A; Kalinsky K; Baurain JF; Jimenez MM; Garcia MM; Berger MD; Lauer UM; Khattak A; Carrato A; Zhang Y; Liu K; Cha E; Keegan A; Bhatta S; Strassburg CP; Roohullah A ESMO Open; 2023 Apr; 8(2):100884. PubMed ID: 36863095 [TBL] [Abstract][Full Text] [Related]
17. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
18. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report. Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J Front Oncol; 2020; 10():611. PubMed ID: 32457834 [No Abstract] [Full Text] [Related]
19. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371 [TBL] [Abstract][Full Text] [Related]
20. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. Kaufman HL; Amatruda T; Reid T; Gonzalez R; Glaspy J; Whitman E; Harrington K; Nemunaitis J; Zloza A; Wolf M; Senzer NN J Immunother Cancer; 2016; 4():12. PubMed ID: 26981242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]